Last reviewed · How we verify
MN-221
At a glance
| Generic name | MN-221 |
|---|---|
| Also known as | Bedoradrine Sulfate, bedoradrine, bedoradrine sulfate |
| Sponsor | MediciNova |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety of MN-221 in Subjects With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PHASE1)
- Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma (PHASE2)
- Safety Study to Evaluate MN-221 in Chronic Obstructive Pulmonary Disease (COPD) Patients (PHASE1)
- Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma (PHASE2)
- Study Evaluating the Safety and Effects of MN-221 in Subjects Experiencing an Acute Exacerbation of Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MN-221 CI brief — competitive landscape report
- MN-221 updates RSS · CI watch RSS
- MediciNova portfolio CI